Jazz Pharmaceuticals, a specialty pharmaceutical company, has hired Kathryn Falberg as senior vice president (SVP) and chief financial officer (CFO). Falberg brings to Jazz Pharmaceuticals more than 20 years of financial officer and director experience. As CFO she will be responsible for the company’s accounting, corporate finance, financial planning, investor relations, and treasury functions.
Falberg joins from ARCA biopharma, where she served as CFO and chief operating officer (COO). From 2001 until joining ARCA in 2009, she worked as an active investor and consultant to small companies and served as a corporate director/audit committee chair for several companies. From 1995 through 2001, Falberg was with Amgen, where she served as SVP finance, strategy and CFO, and before that as vice president, controller and chief accounting officer (CAO), and vice president, treasurer. She currently serves on the Boards of Directors for ESS Technology, Halozyme Therapeutics and QLT.
Falberg received an MBA and BA in Economics from the University of California, Los Angeles, and is a certified public accountant (CPA).
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.